Anavex Lf SC Cm (AVXL) 4.64 $AVXL
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 4.64 (-0.06)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
AVXL: 4.64 (-0.06)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
AVXL: 4.64 (-0.06)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats.
AVXL: 4.64 (-0.06)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 4.64 (-0.06)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 4.64 (-0.06)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 4.64 (-0.06)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 2.36 (-0.01), TPUB: 13.16 (+0.15), AVXL: 4.64 (-0.06), NEOT: 1.28 (-0.03)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).
AVXL: 4.64 (-0.06)
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
GlobeNewswire - Mon Mar 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.
AVXL: 4.64 (-0.06)
Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 50.55 (+0.40), DLTR: 91.25 (+0.63), AVXL: 4.64 (-0.06), CLDX: 4.66 (-0.20), LOCO: 11.67 (-0.03), WTW: 15.40 (+0.05)
Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
GlobeNewswire - Thu Mar 10, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer's trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company's planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer's disease.
AVXL: 4.64 (-0.06)
Identifying Future Exponential Growth in Biotech
ACCESSWIRE - Mon Mar 07, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
AVXL: 4.64 (-0.06)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Anavex Life Sciences Corp. and a Lead Plaintiff Deadline of February 29, 2016 - AVXL
GlobeNewswire - Fri Feb 19, 1:48PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015.
AVXL: 4.64 (-0.06)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Anavex Life Sciences Corp. of Upcoming Deadline -- AVXL
GlobeNewswire - Fri Feb 19, 6:00AM CST
Rigrodsky & Long, P.A.:
AVXL: 4.64 (-0.06)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company" (NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline.
AVXL: 4.64 (-0.06)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 4.64 (-0.06)
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Anavex Life Sciences Corp. (AVXL) and Lead Plaintiff Deadline: February 29, 2016
ACCESSWIRE - Wed Feb 10, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / February 10, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the U.S. District Court for the Southern District of New York under 15-cv-10162, is on behalf of those who purchased shares of Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq: AVXL) between May 17, 2013 and December 28, 2015, inclusive (the "Class Period". Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484.
AVXL: 4.64 (-0.06)
SHAREHOLDER ALERT: Lundin Law PC Announces Ongoing Investigation of Anavex Life Sciences Corp. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Tue Feb 09, 9:57PM CST
Lundin Law PC announces it is investigating claims against Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq: AVXL) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Anavex were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
AVXL: 4.64 (-0.06)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 4.64 (-0.06)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT. AVXL: 4.64 (-0.06)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome. AVXL: 4.64 (-0.06)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats. AVXL: 4.64 (-0.06)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 4.64 (-0.06)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016. AVXL: 4.64 (-0.06)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 4.64 (-0.06)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 2.36 (-0.01), TPUB: 13.16 (+0.15), AVXL: 4.64 (-0.06), NEOT: 1.28 (-0.03)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD). AVXL: 4.64 (-0.06)
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
GlobeNewswire - Mon Mar 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. AVXL: 4.64 (-0.06)
Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 50.55 (+0.40), DLTR: 91.25 (+0.63), AVXL: 4.64 (-0.06), CLDX: 4.66 (-0.20), LOCO: 11.67 (-0.03), WTW: 15.40 (+0.05)
Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
GlobeNewswire - Thu Mar 10, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer's trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company's planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer's disease. AVXL: 4.64 (-0.06)
Identifying Future Exponential Growth in Biotech
ACCESSWIRE - Mon Mar 07, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
AVXL: 4.64 (-0.06)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Anavex Life Sciences Corp. and a Lead Plaintiff Deadline of February 29, 2016 - AVXL
GlobeNewswire - Fri Feb 19, 1:48PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015.
AVXL: 4.64 (-0.06)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Anavex Life Sciences Corp. of Upcoming Deadline -- AVXL
GlobeNewswire - Fri Feb 19, 6:00AM CST
Rigrodsky & Long, P.A.:
AVXL: 4.64 (-0.06)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company"
(NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline. AVXL: 4.64 (-0.06)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 4.64 (-0.06)
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Anavex Life Sciences Corp. (AVXL) and Lead Plaintiff Deadline: February 29, 2016
ACCESSWIRE - Wed Feb 10, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / February 10, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the U.S. District Court for the Southern District of New York under 15-cv-10162, is on behalf of those who purchased shares of Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq: AVXL) between May 17, 2013 and December 28, 2015, inclusive (the "Class Period". Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484. AVXL: 4.64 (-0.06)
SHAREHOLDER ALERT: Lundin Law PC Announces Ongoing Investigation of Anavex Life Sciences Corp. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Tue Feb 09, 9:57PM CST
Lundin Law PC announces it is investigating claims against Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq: AVXL) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Anavex were false and misleading and/or failed to disclose material information regarding the Company's financial performance. AVXL: 4.64 (-0.06)
